Asthma doesn’t seem to expand the danger of contracting COVID-19, shows study Kumar Jeetendra | July 6, 2020 Asthma doesn’t seem to increase the risk for an individual contracting COVID-19 or influence its own seriousness, as shown by a group of Rutgers research workers. “However, individuals with allergies –even those with diminished lung function that are being treated to control asthmatic inflammation–appear like no worse influenced by SARS-CoV-2 compared to the usual non-asthmatic …
Propelled investigation offers new experiences into safe framework’s job in serious COVID-19 Kumar Jeetendra | August 14, 2020 By conducting complex diagnoses of immune system stimulation in patients with acute COVID-19, researchers at Karolinska Institutet have managed to spot several cell types that play a key part in the immune reaction to the new coronavirus and the hyperinflammation found in severe cases of the disease. The results are published in the scientific journal …
Aerogen: An appropriate aerosol drug delivery system for the effective treatment of respiratory illness Kumar Jeetendra | September 1, 2020 No matter what the respiratory illness, for mechanically ventilated or spontaneous breathing patients, Aerogen has the appropriate aerosol drug delivery system for the effective treatment of your patients. The illness includes: 1.COPD 2.Asthma 3.Cystic Fibrosis COPD Chronic Obstructive Pulmonary Disease (COPD) is among the very serious lung diseases prevalent today affecting 65 million people globally. …
Antibiotics directed before age 2 are connected to ongoing conditions Kumar Jeetendra | November 16, 2020 In a retrospective case study, Mayo Clinic researchers have found that antibiotics administered to children younger than 2 are associated with several ongoing illnesses or ailments, which range from allergies to obesity. The findings appear in Mayo Clinic Proceedings. Using health record data from the Rochester Epidemiology Project, a population-based research cooperation in Minnesota and …
Study: Most pregnant patients tested positive for Covid were asymptomatic Kumar Jeetendra | December 12, 2020 The pregnant patients who tested positive for the coronavirus were also more likely than those who tested negative to identify as Hispanic and report their primary language as Spanish. In a retrospective cross-sectional analysis of worldwide screenings for SARS-Cov-2, the virus which causes COVID-19, implemented in the labor and delivery unit of Elmhurst Hospital in …
Genetic variants that sway protein restricting in immune cells can cause autoimmune disease Kumar Jeetendra | April 17, 2021 Certain genetic variants that cause modified protein binding in immune cells, are also seen in people at high risk of some autoimmune diseases, new research has found. Researchers from the Wellcome Sanger Institute, Josep Carreras Leukaemia Research Institute in Spain, and the MRC London Institute of Medical Sciences (LMS) discovered that specific genetic variants, which …
NIAID sets up a clinical research organization to improve comprehension of child asthma Kumar Jeetendra | April 25, 2021 This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop prevention and treatment approaches tailored to children of low-income families residing in urban communities. NIAID plans to provide approximately $70 million over seven years to support the CAUSE network. This new initiative expands and extends NIAID’s long-standing attempts …
Cipla launches initiative to improve access to nebulisers for acute asthma management in primary health care centres of rural India Kumar Jeetendra | December 10, 2021 Mumbai, 10th December 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced a first-of-its-kind initiative to improve access to nebulization therapy specifically for patients in the rural sections of the country. With Cipla’s unmatched presence across the care continuum and a wide range of drug-device combinations and treatments, the …
Inhalation Sciences signs IRS contract worth 1.39 million SEK with new US respiratory pharma client Kumar Jeetendra | September 16, 2022 The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB’s leading in vitro lung simulation tool DissolvIt®. DissolvIt® has been increasingly recognized in the inhalation industry as a leading …
